ACR CONVERGENCE 2020—Rheumatologists and patients have struggled with a lack of new therapies for systemic lupus erythematosus (SLE), but a better understanding of the underlying mechanisms behind the disease helps shed light on potential treatments. That was the theme of the ACR Convergence session State of the Art: Lupus—The Future Is Now, led by Peggy…
Roberto Caricchio, MD, discusses what trials of repurposed rheumatology drugs to treat COVID-19 cytokine storm have shown so far.
Certain nutrients or dietary patterns may affect inflammation and rheumatic disease risk in certain populations. Recommended nutrients include omega-3 fatty acids found in fish, poultry or nuts. Following a Mediterranean or standard Western diet may affect RA risk too.
ACR CONVERGENCE 2020—Although rheumatologists have struggled with a lack of new therapies for systemic lupus erythematosus (SLE), recent positive trial results have brought renewed hope for more treatments. That was the theme of the ACR Convergence 2020 session, State of the Art: Lupus—The Future Is Now, led by Peggy Crow, MD, the Benjamin M. Cohen…
Vaneet K Sandhu, MD, FACR, RhMSUS, discusses how rheumatologists should persevere and collaborate with colleagues to overcome the challenges of the pandemic.
ACR CONVERGENCE 2020—Among the many ways in which the COVID-19 pandemic has changed the face of modern medicine is the emergence of multisystem inflammatory syndrome in children (MIS-C), a rare but serious condition that shares many features of Kawasaki disease (KD). With this topic in mind, leading pediatric experts from around the world came together…
The Year in Review session during ACR Convergence 2020 will address advances in clinical and basic science related to rheumatology, including drug safety, precision medicine, the COVID-19 pandemic and more.
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease of immune dysregulation characterized by unchecked inflammatory responses leading to end-organ dysfunction. Primary HLH results from inherited mutations that impair the capacity for immune regulation; secondary HLH arises from the inappropriate response to an immune stimulus, such as infection, malignancy or autoimmunity. What is less well known is…
Canakinumab, an interleukin (IL) 1 blocker, can now be prescribed to treat patients with active Still’s disease and adult-onset Still’s disease (AOSD)…
Primary hemophagocytic lymphohistiocytosis (HLH) is caused by genetic mutations and inherited syndromes; it therefore occurs in the pediatric age group. Secondary HLH, however, is more common in adults and is often triggered by other disease states, such as malignancies, chronic immunosuppression, infections and autoimmune disease.1,2 Macrophage activation syndrome (MAS) is a subset of secondary HLH…